cx-1739
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02735629)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Glutamate receptor ionotropic AMPAPOSITIVE ALLOSTERIC MODULATOR
Glutamate receptor ionotropic AMPA positive allosteric modulator
Ampakine molecule.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3707399 ↗
Also known as
- cx1739
- cx1739
- cx-1739
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02735629 | Phase 2 | Mar 1, 2016 | Duke University, RespireRx |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| RespireRx | For profit | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1